ProCE Banner Activity

Pharmacologic Management Options for Patients With Tardive Dyskinesia

Podcast Episodes
Listen to Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, discuss the utility of VMAT2 inhibitors for tardive dyskinesia. The experts also touch on off-label and emerging options for tardive dyskinesia, giving healthcare professionals a wealth of information on pharmacologic management.

Released: October 17, 2022

Expiration: October 16, 2023

No longer available for credit.

Share

Faculty

Diana O. Perkins

Diana O. Perkins, MD, MPH

Professor, Psychiatry
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Rajiv Tandon

Rajiv Tandon, MD

Emeritus Professor of Psychiatry
Department of Psychiatry
Western Michigan University Homer Stryker MD College of Medicine
Kalamazoo, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Diana O. Perkins, MD, MPH

Professor, Psychiatry
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Diana O. Perkins, MD, MPH: consultant: Karuna; other financial or material support: Alkermes.

Rajiv Tandon, MD

Emeritus Professor of Psychiatry
Department of Psychiatry
Western Michigan University Homer Stryker MD College of Medicine
Kalamazoo, Michigan

Rajiv Tandon, MD, has no relevant financial relationships to disclose.